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Figure 1.
Pathological examination
28
OSNA
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Table 1:
Characteristic No. of patients (%)
Total cohort 128
Sex
   
Tumorlocation
  
   
   pN1
TNM stage
 I
   II
   III
  
   Poor
Table 2:
Routine pathological examination (SLNs)
Positive Negative Total
OSNA (SLNs) Positive 23 43
Negative 5 79 84
Total 28 99 127
Positive 29 36 65
Negative 63 63
Total 29 99 128
Positive 29 46 75
Negative 53 53
Total 29 99 128
SLNs: Sentinel Lymph Nodes
* FP: using anti-Pan-Cytokeratin antibody (LU-5) staining as described in the material and methods section
** Results of OSNA and FP of SLNs were combined. A patient was considered positive when in one or both methods a 
positive SLN was found and negative when with both methods negative SLNs were found.
31
2
Table 3:
Fine pathological examination (SLNs)
Positive Negative Total
OSNA (SLNs) Positive 33 43
Negative 31 53 84
Total 64 63 127
SLNs: Sentinel Lymph Nodes
* FP: using anti-Pan-Cytokeratin antibody (LU-5) staining as described in the material and methods section
Table 4: 
pN+ pN0 Total
OSNA (SLNs) Positive 27 16 43
Negative 16 68 84
Total 43 84 127
Positive 35 65
Negative 9 54 63
Total 44 84 128
Positive 36 39 75
Negative 8 45 53
Total 44 84 128
SLNs: Sentinel Lymph Nodes
* FP: using anti-Pan-Cytokeratin antibody (LU-5) staining as described in the material and methods section
** Results of OSNA and FP of SLNs were combined. A patient was considered positive when in one or both methods a 
positive SLN was found and negative when with both methods negative SLNs were found.
*** Lymph nodes routinely assessed in the resection material by a pathologist using H&E staining.
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the near future. 
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ex vivo
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SUPPLEMENTARY MATERIAL
ti
Separated by hospital
Jeroen Bosch Hospital
pN+ pN0 pN+ pN0
OSNA (SLNs) Positive
Negative
Total
Positive
Negative
Total
SLNs: Sentinel Lymph Nodes
* FP: using anti-Pan-Cytokeratin antibody (LU-5) staining as described in the material and methods section
** LUMC: Leiden University Medical Center
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44
Table 1:
Jeroen Bosch Hospital LUMC
Total number of patients (N) 67         19 -
Gender (%)
#
#
Approach (%)
#
Pathological tumor stage (%)
#
Pathological nodal stage (%)
N1
N2
-
(..) = %, # = Pearson Chi-Square Asympt. (2-sided), LUMC: Leids Universitair Medisch Centrum 
45
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Table 2:
Recurrence
                                                                           No      Yes
OSNA (SLNs)
Table 3:
Disease free survival
Estimate 95%CI
62.5
57.6-66.3
58.1 51.6-64.6
62.9 58.2-67.7
Cox regression Disease free survival
HR 95%CI
1.47
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Table 1:
Gelre Hospital Jeroen Bosch Hospital
Total number of patients (N) 125 67
Gender (%)
#
4
$
Approach  (%)
$
Pathological tumor stage
Cis $
$
Occult tumor cells
$
IQR= interquartile range, Cis = carcinoma in situ. *= Mann Whitney U test; # = Pearson Chi-Square Exact Sig. (2-sided);
$= Fisher Exact Test Exact Sig. (2-sided)
59
4
Table 2:
Total number of patients
no occult 
tumor cells
 (n=147)
isolated 
tumor cells 
(n=37)
micrometastases
(n=8)
Resection technique (%)
$
Tumor stage (%)
Cis $
Poor
$
Angioinvasive growth (%) $
No $
*= Krukskal Wallis test; # = Pearson Chi-Square Exact Sig. (2-sided); $= Fisher Exact Test Exact Sig. (2-sided); ^= linear 
by linear association (2-sided)
Occult tumour cells as prognostic marker
Table 3:
Distant metastasis (n=14); Adjuvant
treatment
Locoregional metastasis Adjuvant
treatment
No occult tumour cells 
n=9 out of 147
recurrence rate 6.1%
No
No
No
No
No
No
No
No
No
ITCs
n=4 out of 37
recurrence rate 10.8%
No
No
No
No
MMs 
n=3 out of 8
recurrence rate 37.5%
No
No
Time until recurrence 
No occult tumour cells vs ITC p= 0.299^, no occult tumour cells vs MMs p = 0.016^. 
61
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No occult tumor cells
146 133 84 56 35
6 7 7 9
Isolated tumor cells
36 32 14 5 2
2 4 4 4
Micrometastasis
8 6 5 5
2 3 3 3
P-value of logrank =0.005
Figure 1:
62
Table 4:
Univariable Multivariable
OR 95%CI OR 95%CI
MMs  7.892 1.695-36.756 7.667
DISCUSSION
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Supplemental table 2:
Gene Region RefSeq mRNA ID (GRCh37/Hg19) Panel
ACVR1B 1
ACVR2A 1
ARID1A 1
AXIN2 1
B2M 1
CASP8 1
CDC27 1
ELF3 1
ERBB3 1
FBXW7 1
GOT1 1
MSH3 1
NTN4 1
PCBP1 1
RHOA 1
RNF43 1
SIRT4 1
SMAD2 1
SOX9 1
TCF7L2 1
TGFBR2 1
TRIM23 1
AKT1 Codon 17 2
APC 2
BRAF Codons 582-615 2
CDH1 2
CDKN2A (p14) 2
CDKN2A (p16) 2
CTNNB1 Codons 19-48 2
CXCR4 Codons 281-357 2
EGFR Codons 434-499 2
EPCAM 2
ERBB2 2
EZH2 2
GNA11 2
GNAQ 2
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GNAS 2
H3F3A Codons 28 and 35 2
H3F3B Codon 37 2
HRAS Codons 12, 13, 59 and 61 2
IDH1 Codon 132 2
IDH2 2
JAK2 Codon 617 2
KIT Codons 412-513 2
KRAS Codons 12, 13, 59, 61, 117 and 146 2
MLH1 2
MPL Codon 515 2
MSH2 2
MSH6 2
MYD88 2
NRAS Codons 12, 13, 59, 61, 117 and 146 2
PDGFRA Codons 552-596 2
PIK3CA 2
POLD1 2
POLE 2
PTEN 2
SF3B1 2
SMAD4 2
TERT Promotor region 2
TP53 2
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